Belite Bio Submits NDA in Japan for Tinlarebant Under Sakigake Designation
BLTE has more than doubled off its 52-week low of $64.8 on elevated volume (3.8× avg).
Summary
Belite Bio submitted an NDA to Japan's MHLW for tinlarebant in Stargardt disease type 1 under the Sakigake designation, expanding its regulatory push beyond the U.S. FDA Priority Review.
Key Events · Product Development and Regulatory · BLTE
-
Japan NDA Submission
A New Drug Application has been filed with Japan's MHLW for tinlarebant in Stargardt disease type 1 under the Sakigake Designation System.
-
First-in-Class Potential
If approved, tinlarebant would be the first-ever approved treatment for STGD1 and the first Sakigake pharmaceutical product for ophthalmology disease in Japan.
-
Market Opportunity
STGD1 affects an estimated 9,500 people in Japan, with no currently approved treatment options.
-
Regulatory Momentum
Follows the U.S. FDA's acceptance of the NDA with Priority Review and a PDUFA target action date of February 12, 2027.
Analysis · BLTE · Life Sciences
A New Drug Application has been filed with Japan's MHLW for tinlarebant in Stargardt disease type 1, leveraging the Sakigake expedited review pathway. This expands the regulatory footprint beyond the U.S. FDA, where the NDA is already under Priority Review with a PDUFA date of February 12, 2027. If approved, tinlarebant would be the first-ever treatment for STGD1 and the first Sakigake-designated ophthalmology product in Japan, addressing an estimated 9,500 patients in that market. The filing signals continued global commercialization momentum for the company's lead asset.
How filings like this one have moved
In the 30 days to Sep 10, 2026, 35.8% of the 1864 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, BLTE was trading at $193.61 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $7.8B. The 52-week trading range was $64.80 to $200.00. This filing was assessed with positive market sentiment and an importance score of 8 out of 10.